A case of 177Lu-DOTATATE therapy without the use of antiemetics
JG Peacock, B O'Sullivan… - Journal of Nuclear …, 2021 - Soc Nuclear Med
Recommended 177Lu-DOTATATE treatment regimens involve prophylaxis with antiemetics
to counteract the emetogenic properties of the nephroprotective amino acid solution …
to counteract the emetogenic properties of the nephroprotective amino acid solution …
Comparison of Patient Experience with Commercial Versus Compounded Amino Acid Infusion for 177Lu-DOTATATE Therapy
E Padilla-Morales, A Tan, T Hope, E Bergsland - 2019 - Soc Nuclear Med
2015 Objectives: A variety of medications are given to 177Lu-DOTATATE peptide receptor
radionuclide therapy patients as a preventative measure to alleviate nausea and protect …
radionuclide therapy patients as a preventative measure to alleviate nausea and protect …
[PDF][PDF] Amino Acid Solutions for 177Lu-Oxodotreotide Premedication: A Tolerance Study. Cancers 2022, 14, 5212
P Courault, A Deville, V Habouzit, F Gervais, C Bolot… - 2022 - academia.edu
Background: The co-infusion of amino acid solutions during peptide receptor radionuclide
therapy reduces the tubular reabsorption of 177Lu-oxodotreotide, thus minimizing …
therapy reduces the tubular reabsorption of 177Lu-oxodotreotide, thus minimizing …
[HTML][HTML] Amino Acid Solutions for 177Lu-Oxodotreotide Premedication: A Tolerance Study
P Courault, A Deville, V Habouzit, F Gervais, C Bolot… - Cancers, 2022 - mdpi.com
Simple Summary [177Lu] oxodotreotide (Lutathera®) was approved by the European
Medical Agency in 2017 and the Food and Drug Administration in 2018 for the treatment of …
Medical Agency in 2017 and the Food and Drug Administration in 2018 for the treatment of …
Evaluation of the incidence of acute nausea and vomiting after administration of an amino acid solution containing only arginine and lysine with lutetium Lu-177 …
N Alonzo, M Seyer, EJ Kim, R Keshavarzi, K Yee… - 2020 - ascopubs.org
12113 Background: Lutetium Lu-177 dotatate is used to treat patients with
gastroenteropancreatic neuroendocrine tumors, and an amino acid (AA) solution must be …
gastroenteropancreatic neuroendocrine tumors, and an amino acid (AA) solution must be …
Risk of Radiation Exposure to Clinical Staff from Paracenteses of Large-Volume Chylous Ascites After 177Lu-DOTATATE Infusion
S Tipnis, WJ Rieter, L Gordon - Journal of Nuclear Medicine …, 2022 - Soc Nuclear Med
177Lu-DOTATATE has gained wide clinical acceptance for the treatment of advanced
gastroenteropancreatic neuroendocrine tumors; however, little is known regarding its …
gastroenteropancreatic neuroendocrine tumors; however, little is known regarding its …
Dosing lutetium Lu 177‐dotatate for a hemodialysis patient
L Taylor, R Meades, AM Quigley… - Hemodialysis …, 2024 - Wiley Online Library
Abstract Lu177‐dotatate (Lutathera™) is a radioactive drug approved for the treatment of
adults with gastro‐entero‐pancreatic neuroendocrine tumors and is predominantly renally …
adults with gastro‐entero‐pancreatic neuroendocrine tumors and is predominantly renally …
Initial experience and lessons learned with implementing Lutetium-177-dotatate radiopharmaceutical therapy in a radiation oncology–based program
Purpose To assist radiation oncology centers in implementing Lutetium-177-dotatate (177
Lu) radiopharmaceutical therapy for midgut neuroendocrine tumors. Here we describe our …
Lu) radiopharmaceutical therapy for midgut neuroendocrine tumors. Here we describe our …
Comparison of Two Types of Amino Acid Solutions on 177Lu-Dotatate Pharmacokinetics and Pharmacodynamics in Patients with Metastatic Gastroenteropancreatic …
M Lambert, L Dierickx, S Brillouet… - Current …, 2022 - ingentaconnect.com
Background: 177Lu-Dotatate is used in the treatment of somatostatin-receptor-positive
inoperable progressive gastroenteropancreatic neuroendocrine tumors. A co-infusion of …
inoperable progressive gastroenteropancreatic neuroendocrine tumors. A co-infusion of …
Nuts and bolts of 177Lu-DOTATATE administration in the nuclear medicine division: guidance from a single institute's experience
A Abbott, CG Sakellis, E Andersen… - Journal of Nuclear …, 2018 - Soc Nuclear Med
[Lutetium-177-DOTA (0), Tyr (3)] octreotate (177 Lu-DOTATATE) is a radiolabeled
somatostatin analog that has been approved by the US Food and Drug Administration for …
somatostatin analog that has been approved by the US Food and Drug Administration for …
Related searches
- 177lu dotatate use of antiemetics
- 177lu dotatate patient experience
- 177lu dotatate neuroendocrine tumors
- 177lu dotatate dosimetric analyses
- 177lu dotatate clinical staff
- 177lu dotatate chylous ascites
- 177lu dotatate nuts and bolts
- 177lu dotatate technical aspects
- 177lu dotatate pituitary gland
- 177lu dotatate radiation exposure
- acid solutions 177lu oxodotreotide
- 177lu dotatate pharmacodynamics in patients